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http://dx.doi.org/10.1016/j.ccell.2015.04.004SUMMARYLeukemic cells disrupt normal patterns of blood cell formation, but little is understood about the mechanism.
We investigated whether leukemic cells alter functions of normal hematopoietic stem and progenitor cells.
Exposure to chronic myelogenous leukemia (CML) caused normal mouse hematopoietic progenitor cells
to divide more readily, altered their differentiation, and reduced their reconstitution and self-renewal poten-
tial. Interestingly, the normal bystander cells acquired gene expression patterns resembling their malignant
counterparts. Therefore, much of the leukemia signature is mediated by extrinsic factors. Indeed, IL-6 was
responsible for most of these changes. Compatible results were obtained when human CML were cultured
with normal human hematopoietic progenitor cells. Furthermore, neutralization of IL-6 prevented these
changes and treated the disease.INTRODUCTION
Most hematopoietic stem cells (HSCs) reside in the bone marrow
and self-renew as necessary to maintain their numbers (Mercier
et al., 2012). Additionally, a fraction of HSCs develop into pro-
genitor cells that become lineage restricted and that undergo
extensive proliferation and differentiate to produce mature he-
matopoietic cells (Mayle et al., 2013; Venezia et al., 2004; Wilson
et al., 2008). However, these normal processes are severely
compromised with leukemia (Colmone et al., 2008; Hartwell
et al., 2013; Hu et al., 2009; Krause et al., 2013; Schepers et al.,
2013). While this could result from overcrowding by leukemic
cells, it has been shown to occur with even low leukemic burden
(Colmone et al., 2008). Considerable progress has been made in
defining cells within marrow that support normal hematopoiesisSignificance
It has generally been assumed that normal hematopoietic st
for space by malignant cells. We have shown that the leuke
non-transformed cells while promoting their own maturation. T
tional programs onto the non-transformed progenitors. Howev
the differentiation bias and eliminate the bulk of the disease. Ad
cells, and leukemic-exposed human progenitors could be prote
mechanism that could account for significant malignancy-rela(Morrison and Scadden, 2014). Referred to as niches, these envi-
ronments are thought to includemultipotent stromal cells (MSCs),
osteoblasts, and endothelial cells. Additionally, there is now evi-
dence that leukemia alters their functions (Raaijmakers et al.,
2010; Reynaud et al., 2011; Schepers et al., 2013; Zhang et al.,
2012). However, consequences of those changes and the direct
impact of the leukemic cells on stemandprogenitor cells have not
been adequately explored.
Myeloproliferative neoplasms are clonal disorders propagated
by transformed HSCs. Chronic myelogenous leukemia (CML) is
one such disorder, and it is characterized by a reciprocal trans-
location of the t(9;22)(q34;q11) loci. As a result, transformed cells
express the BCR/ABL fusion protein (Ben-Neriah et al., 1986;
Hooberman et al., 1989; Levine and Gilliland, 2008; Savona
and Talpaz, 2008; Sawyers, 1999; Witte, 1988). This deregulatedem and progenitor cells (HSPCs) are simply out-competed
mic cells are able to modify the differentiation potential of
he leukemic environment imprints functional and transcrip-
er, by specifically blocking the IL-6 cytokine, we could inhibit
ditionally, these observationswere also found in humanCML
cted by anti-IL-6. These findings implicate a drug-targetable
ted abnormalities in CML.
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Figure 1. Experimental Design and Establishment of a Chimera
Chronic Leukemia Model
(A) Overview of the experimental design for generation of CML chimeras, 2 3
106 whole bone marrow (WBM) cells from either C57BL/6 mice (CD45.2;
Control) or Scl-tTa-BCR-ABL (CD45.2; Transgenic) mice mixed with 2 3 106
C57BL/6 cells congenic for the CD45 locus (CD45.1; Normal) and transplanted
into mice on Tet. Chimerism was established for 16 weeks before Tet with-
drawal and induction of BCR-ABL in those cells carrying the two transgenes.
Tissue cells were obtained 4 weeks after induction, and CD45.1+ cells from
control transplants, leukemic-exposed cells (CD45.1+ cells from leukemic
mice), or leukemic cells (CD45.2+ transgenic cells from leukemic mice) were
analyzed.
(B) Survival curves of control and transgenic chimeric mice after Tet with-
drawal.
(C) The CD45.1 chimerism results are based on the staining of lymphoid (B220/
CD3) and myeloid (Mac1/Gr1) cells in PB versus CD45.2 (control or leukemic)
over time; n = 4 per time point. Error bars represent mean ± SEM.
(D) Upper panel: representative FACS profiles from four experiments char-
acterizing the PBof control or leukemicmice showing the chimerism of CD45.1
versus CD45.2 from control or transgenic chimeric mice 4 weeks after Tet
removal. Lower panel: FACS profiles of CD45.1 cells in the PB of control or
leukemic mice at 4 weeks after Tet removal. Cells were stained for B220/CD3
and B220/Mac1-Gr1. Cells that stain positive for both fluorochromes are
B-lineage cells (B220+), while those that stain only for B220/CD4 and CD8 are
T-lineage cells (CD4/8), and those cells that are positive for only B220/Mac1-
Gr1 are of the myeloid lineage (Mac1-Gr1). Leuk Exp, leukemic exposed.
(E) Representative FACS profiles from the bone marrow gating for CD45.1+ B-
lineage cells (B220+ CD43+/) of either control or transgenic chimeric mice at
4 weeks after Tet withdrawal. Dot plots from leukemic cells (CD45.2) from the
transgenic chimeric mice are shown for comparison (right). Similarly, bone
marrow and spleens from control and transgenic chimeric mice were analyzed
for the CD45.1+ myeloid-lineage cells (Mac1+ and Gr1+), and leukemic cells
(CD45.2+) are shown for comparison, n = 5.
See also Figure S1.
672 Cancer Cell 27, 671–681, May 11, 2015 ª2015 Elsevier Inc.tyrosine kinase promotes leukemic growth by disrupting sig-
naling pathways involved in cell survival, proliferation, and differ-
entiation. The chronic phase of CML presents with increased
numbers of circulating progenitors, anemia, and splenomegaly
(Petzer et al., 1996). At this time, leukemia-initiating cells (LICs)
that can propagate disease are still present (Schemionek et al.,
2010; Zhang et al., 2010) and retain the ability to make all blood
cells, generating a vast expansion of malignant myeloid cells that
displace normal hematopoiesis (Fialkow et al., 1977). In mice,
these transformed progenitors are phenotypically similar to
normal HSCs and are enriched within the Lin Sca1+ c-KitHi frac-
tion of bone marrow (KSL) (Holyoake et al., 1999; Hu et al., 2006;
Maguer-Satta et al., 1996; Wang et al., 1998). Furthermore, pro-
cesses that control normal HSC functions are also essential for
LIC maintenance (Heidel et al., 2012; Lessard and Sauvageau,
2003; Reynaud et al., 2011; Warr et al., 2011; Zhao et al., 2007).
The chronic phase of CML cannot be efficiently modeled by
transplantation of human cells into immunodeficient mice (Dazzi
et al., 1998; Zhang et al., 2010). Therefore, our laboratory devel-
oped a BCR-ABL-inducible mouse model that results in expres-
sion of this oncogenic fusion under the control of a tetracycline
(Tet)-regulated 30 enhancer of the murine stem cell leukemia
(SCL) gene (Koschmieder et al., 2005; Schemionek et al.,
2010). SCL-tTA 3 BCR-ABL double transgenic mice develop a
disease similar to the chronic-phase CML observed in patients.
BCR-ABL expression following Tet withdrawal results in neutro-
philic leukocytosis and splenomegaly. The chronic phase is
characterized by progressive myeloid expansion, with accumu-
lation of myeloid progenitors and mature granulocytes in the
marrow and peripheral blood (PB) (Koschmieder et al., 2005;
Schemionek et al., 2010). These CML cells are functionally het-
erogeneous and capable ofmaintaining a normal hierarchical dif-
ferentiation process (Reynaud et al., 2011; Zhang et al., 2012).
This model made it possible to study normal hematopoietic
cells while in close proximity to their leukemic counterparts by
transplanting inducible leukemic transgenicmarrowcells together
with normal marrow cells and monitoring the effects of exposure
of leukemic cells on normal HSPC function. It is important to
note that the leukemic cells altered the properties of normal
HSCs and progenitors, and preventing these environmental
changes has important therapeutic implications for the disease.
RESULTS
Leukemic CML Cells Induce a Myeloproliferative Effect
on Normal Hematopoietic Cells
Previous studies from our laboratory and others using this induc-
ible model of CML identified leukemia-initiating activity in the
stem/progenitor fraction of the marrow (Reynaud et al., 2011;
Schemionek et al., 2010; Zhang et al., 2010). To explore the
effects of leukemic cells on normal hematopoietic (leukemic-
exposed) cells, C57BL/6-CD45.1 (normal) plus SCL-tTA 3
BCR-ABL-CD45.2 (transgenic) whole marrow cells were trans-
planted into lethally irradiated C57BL/6-CD45.1 mice. As
controls, 2 3 106 whole marrow cells from C57BL/6-CD45.1
(normal) plus the same number from C57BL/6-CD45.2 (normal)
mice were transplanted (Figure 1A). Recipients were then kept
on Tet water for 16 weeks to establish homeostasis within the
chimeric mice. Upon removal of Tet, mice bearing transgenic
Figure 2. Normal Progenitor Profiles within the Leukemic Envi-
ronment
(A) Flow cytometry profiles for control and leukemic-exposed (Leuk Exp)
progenitors (CD45.1+) of Lin ckitHi Sca1+ (KSL) and Lin ckitHi Sca1+ CD150+
CD48 (HSC), in either control or leukemic marrow at 4 weeks after Tet
withdrawal, n = 5.
(B) Numbers of control and leukemic-exposed (CD45.1+) progenitors were
calculated per femur for Lin ckitHi Sca1+ (KSL), Lin ckitHi Sca1+ CD150+
CD48 (HSC), or Lin ckitHi Sca1+ CD34+ Flt3 (ST-HSC) in either control or
leukemic marrow, n = 5. Error bars represent mean ± SEM.
(C) CD45.1+ HSCs (Lin ckitHi Sca1+ CD150+ CD48; HSC) or CD45.1+ KSLs
(Lin ckitHi Sca1+; progenitors) were sorted from either control or leukemic
environments, and then cell cycle status was determined using Pyronin Y and
Hoescht, n = 5. Error bars represent mean ± SD.
(D) BrdU incorporation of CD45.1+ HSCs (KSL CD150+ CD48) from control or
leukemic mice was quantified, and lines indicate the mean; n = 5.
(E) Annexin V staining of control or leukemic-exposed HSCs was used to
determine the apoptosis within this subset of progenitors, and lines indicate
the mean, n = 5.
See also Figure S2.cells developed a disease similar to chronic-phase CML with
severe myeloid cell expansion, coincident with reduction of
lymphoid-lineage cells in the marrow, spleen, and PB. The dis-
ease progressed so that 4 weeks after induction, elevated
PB leukocyte counts were observed (Figure S1A), with increased
cellularity in the spleen and decreased cellularity in the marrow.
Chimeric mice with transgenic cells succumbed to the disease
with the median survival time of 46 days after Tet withdrawal
(Figure 1B). All mice transplanted with leukemic cells developed
splenomegaly, compared to control transplanted mice (Fig-
ure S1B). Leukemic cells altered the chimerism of normal cells
(CD45.1+, leukemic exposed) within these same mice from the
time of induction as compared to the control transplants. Chime-
rism is shown as the percentage of CD45.1 cells out of the total
CD45-positive cells (CD45.1+ and CD45.2+) (Figure 1C).
Flow cytometry analysis of the PB from chimeric mice showed
increased numbers of donor (CD45.2+) cells in leukemic trans-
plants, compared to those observed in the control mice. Similar
to those of the leukemic population, the leukemic-exposed
(CD45.1+ normal from the leukemic mice) cells also have
increased myeloid lineages with losses in both B and T lineages
in the PB (Figures 1D and S1C). To demonstrate that CD45.1
marked only normal cells lacking the two transgenes, popula-
tions of CD45.1+ and CD45.2+ cells were sorted from leukemic
mice, and only the CD45.2+-sorted cells contained both trans-
genes by PCR analysis: SCL-tTA and BCR-ABL (Figure S1D).
Increased percentage and absolute numbers of myeloid cells
could also be observed in the normal cells of the bone marrow
and spleens of the leukemic mice as compared to control
mice, with a phenotypic representation similar to that of the
leukemic cells (CD45.2+) (Figure 1E). Therefore, our chimeric
mouse model replicates the disease found in primary transgenic
mice. It is important that accumulation ofmyeloid-lineage cells at
the expensive of lymphoid cells was observed in the non-trans-
formed CD45.1+ leukemic-exposed cells, similar to that of the
leukemic cells expressing the BCR-ABL transgene.
Alterations in Normal Stem and Progenitor Cells during
Leukemia
As an initial approach to understand the alterations described
earlier in mature lineages, we performed detailed analyses of
stem and progenitor cells in chimeric marrow. Mice were
analyzed at 4 weeks after leukemic induction, and subsets of
early progenitor populations were evaluated: Lin ckitHi Sca1+
(KSLs, referred to as progenitors), long-term HSCs (HSCs:
CD150+ CD48KSLs, or SLAM+ KSLs, referred to as stem cells),
and short-term HSCs (ST-HSCs: CD34+ Flt3 KSLs; Wilson
et al., 2008) (Figure 2A; Figure S2A). Absolute numbers of normal
leukemic-exposed HSCs were not significantly altered in the
bone marrow of mice with CML. Meanwhile, there were signifi-
cant increases in the leukemic-exposed total KSL and granulo-
cyte-monocyte progenitor (GMP), including specific increases
in ST-HSCs and multipotent progenitors (MPP), as compared
to controls (Figure 2B; Figure S2A). Therefore, the CML leukemic
environment had an altered capacity to support normal progen-
itor cells, changing the distribution of these populations within
4 weeks of disease.
We then assessed the proliferation status and cell cycle of
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there were no observed changes in the HSCs in cycle. Mean-
while, CD45.1+ progenitors from the leukemic environment
were induced to proliferate (Figure 2C; Figure S2B). It was previ-
ously demonstrated that leukemic BCR-ABL+ HSCs have a
hyperproliferative phenotype (Schemionek et al., 2010; Zhang
et al., 2010). However, the leukemic-exposed HSCs showed
little evidence of proliferation as assessed by bromodeoxyuri-
dine (BrdU) incorporation. Conversely, many leukemic-exposed
KSLs were dividing (Figure 2D; Figure S2C). The increase of
BrdU incorporation could be from DNA damage by the leukemic
environment; however, there was no evidence of increased
apoptosis in HSCs from the leukemic environment (Figure 2E;
Figure S2D). Thus, the leukemic environment promoted prolifer-
ation of normal progenitors but not the HSCs from which they
derive.
Leukemic Cells Compromise Functions of Normal Stem
and Progenitor Cells
We wondered if co-habitation with leukemic cells caused
intrinsic changes in otherwise normal stem and progenitor cells.
Normal CD45.1+ KSLs were sorted from either control or
leukemic mice and co-cultured on OP9 stromal cells to allow dif-
ferentiation to the B lineage. It has been previously shown that, in
addition to B cells, myeloid cells can also be produced ineffi-
ciently under these conditions (Mohtashami et al., 2010; Wang
et al., 2005; Welner et al., 2008). The yield of B-lineage cells pro-
duced from normal KSLs was severely decreased by leukemic
exposure with only modest increases in myeloid lineage cells
in this assay, similar to that observed when using leukemic cells
(Figures 3A and 3B).
Many methods have been used for HSC purification (Challen
et al., 2009), but they are functionally defined through transplan-
tation (Kiel et al., 2005; Spangrude et al., 1995; Szilvassy et al.,
1990). To determine how the leukemic cells and their altered
environment impact normal HSCs or KSLs (progenitors), we
transplanted control or leukemic-exposed HSCs into irradiated
CD45.2 congenic recipients (Figure 3C). At 12 hr after transplan-
tation, no significant defects in homing were observed from the
HSC-transplanted mice, similar to results obtained with homing
of leukemic cells (Figure 3D). To test whether the observed in-
crease in leukemic-exposed progenitors reflects differences in
function, we performed competitive repopulation transplants
with limiting numbers of control or leukemic-exposed HSCs.
It is interesting that an approximate 4-fold reduction in stem
cell activity results from exposure to leukemic cells (Figure 3E).
Therefore, a more rigorous test of HSC function was then per-
formed with serial transplantation assays. Since there were
modest differences in HSC numbers between control and
leukemic-exposed populations, we adjusted for these in the
serial transplantations. Residence in a leukemic environment
diminished repopulation capability in one round of transplan-
tation, and this was magnified when the cells were re-trans-
planted to additional recipients (Figure 3F). From similarly trans-
planted mice, lymphoid (B/T) and myeloid reconstitution in
the PB was determined 16+ weeks post-transplant. Leukemic-
exposed HSCs showed no skewing to either myeloid or
lymphoid lineages (Figure 3G, top). However, when recipient
mice were transplanted with KSLs/progenitors and analyzed at
8–10 weeks post-transplant, residence in the leukemic environ-674 Cancer Cell 27, 671–681, May 11, 2015 ª2015 Elsevier Inc.ment increased their myeloid cell production at the expense
of lymphoid lineages (Figure 3G, bottom). Therefore, leukemic
exposure caused discrete alterations in hematopoietic progeni-
tors. KSLs/progenitors had reduced competency for generation
of lymphopoiesis, whereas numbers of more rigorously defined
HSCs were mostly unaffected, and they could produce all
blood lineage cells. However, HSCs were not unscathed,
because their self-renewal and re-populating ability on trans-
plant were compromised.
Normal Progenitors Resemble Transformed CML with
Respect to Molecular Features
Bystander effects of residence within the leukemic environment
were then explored with genome-wide gene profiling of purified
control or leukemic-exposed HSCs and KSLs. The data were
interrogated with several unbiased approaches, focusing on
lineage-specific transcription factors that could account for
changes in function and differentiation toward the myeloid line-
age (Figure 4A). Gene set enrichment analysis (GSEA) was
used to seek similarities between these normal progenitors
and ones with a CML signature. Surprisingly, leukemic-exposed
KSLs acquired a BCR-ABL+ signature of the leukemic cells with
which they reside. In contrast, transcription patterns in leukemic-
exposed HSCs were altered but not to the degree in which they
resembled the leukemic signature (Figure 4B).
We wanted to further investigate the HSC microarray data to
uncover why we see differences in self-renewal and engraftment
upon transplantation. There were 1,468 differentially expressed
genes in the leukemic-exposed HSCs versus control HSCs (Fig-
ure S3A). GSEA was used to determine the correlation of each
dataset with known ‘‘stem-ness’’-related genes. We observed
bias in control HSCs relative to leukemic-exposed HSCs, further
supporting their ability to repopulate mice upon transplantation
(Figure S3B). Significant to this study were changes observed
in signaling pathways potentially altered by the leukemic envi-
ronment which might account for the changes in lineage specifi-
cation specific to the KSLs/progenitors. Several pathways were
shown to be dysregulated in the leukemic-exposed KSLs (Fig-
ure S3C) and might account for the changes we see in engraft-
ment; these will be a focus of our future work. Unlike our findings
with KSLs/progenitors, the leukemic-exposed HSCs showed no
consistent lineage bias in myeloid or lymphoid lineage specific
transcription factors (Figure S3D).
From our analysis of leukemic-exposed HSCs and KSLs/pro-
genitors, we thought that the inflammatory environment might
mediate many of the observed changes. From our model, we
measured serum cytokine levels (Figure 4C). Consistent with
data from others (Reynaud et al., 2011; Zhang et al., 2012),
several inflammatory cytokines, including granulocyte-macro-
phage colony-stimulating factor (GM-CSF), interleukin (IL)-6,
and IL-1a, were significantly increased during leukemogenesis.
These inflammatory cytokines provide one way that the leukemic
environment might impose malignant cell properties on untrans-
formed cells that reside there, as seen with the BCR-ABL GSEA
earlier (Figure 4B). Additionally, GSEA showed that there was an
inflammatory signature in the leukemic cells that was absent in
the leukemic-exposed cells, suggesting that the leukemic cells
are the source of these cytokines (Figure S3E) (Kleppe et al.,
2015). From the current literature and known functions of each
Figure 3. Stem and Progenitor Cell Memory of Leukemic Exposure
(A) CD45.1+ KSLs from either control or leukemic mice were sorted and placed
in OP9 co-culture assay. Flow cytometry analysis of CD19 and Mac1 in these
cultures after 14 days is shown; n = 4. Leuk Exp, leukemic exposed.of these cytokines, IL-6 was further investigated for this cyto-
kine’s role in altering the normal KSL functions within the CML
environment. Again, we used GSEA to ask whether normal
KSLs from the leukemic mice were aligned with an ‘‘IL-6 signa-
ture,’’ as this receptor has little to no expression in HSCs
(Figure S3F) (Maeda et al., 2005). Indeed, this was the case for
the leukemic-exposed progenitors but not leukemic-exposed
HSCs (Figure 4D). Our own observations were consistent with
recent findings that IL-6 was elevated in the leukemic cells of
this mouse model (Figure S3G) (Reynaud et al., 2011).
Furthermore, we wondered whether current therapy was able
to reverse the impact of normal hematopoiesis within CML spe-
cifically with regard to IL-6 production. Currently, imatinib (IM) is
the first-line treatment for CML. Therefore, IM was started
2 weeks after Tet withdrawal, a time point when disease was
consistently initiated as determined by flow cytometry. Mice
were treated by gavage every other day for 4 weeks. After this
treatment, B lymphopoiesis and myeloid differentiation were
restored to their normal ratios (Figure S3H). Additionally, we
sorted CD45.1+ KSLs from the control, IM-treated leukemic, or
leukemic mice and determined their ability to make B-lineage
cells in vitro. Indeed, treatedmice had restored B-lineage poten-
tial (Figure S3I). Moreover, the levels of IL-6 in the serum were
reduced to near-normal levels, even in the presence of minimal
residual disease (2%–15%CD45.2+ cells) (Figure S3J), The phe-
nomenon of altered inflammatory environment by IM has been
recently observed by others as well (Zhang et al., 2010). Taken(B) Quantification of B cells (CD19+) and myeloid-lineage cells (Mac1+) from
OP9 co-cultures were plotted from CD45.1+ KSLs from either control or
leukemic-exposed and CD45.2+ leukemic KSLs 14 days after initiation; n = 4.
Error bars represent mean ± SEM.
(C) Cartoon showing that control or leukemic-exposed CD45.1+ KSLs or HSCs
(Lin ckitHi Sca1+ CD150+ CD48) were sorted from the primary chimeras and
transplanted into sublethally irradiated C57BL/6 (CD45.2) hosts. KSL- trans-
planted mice were analyzed at 10 weeks post-transplant, while HSC-trans-
planted mice were analyzed afterR16 weeks post-transplant.
(D) CD45.2+ leukemic HSCs and CD45.1+ HSCs were sorted from control and/
or leukemic mice and then labeled with CFSE (5(6)-carboxyfluorescein N-hy-
droxysuccinimidyl ester). These cells were then transplanted into lethally
irradiated mice for 12 hr, at which time the femurs were analyzed for the
presence of CFSE and CD45.1+ cells. Plots show homing efficiency relative to
the control HSCs; n = 5. Error bars represent mean ± SD.
(E) Limiting dilution CRU (competitive repopulation unit) assay is shown. The
indicated numbers of control or leukemic-exposed HSCs were transplanted
along with 2 3 105 bone marrow cells of a competitor (CD45.2+) into lethally
irradiated hosts (CD45.2+). Reconstitution was evaluated in the blood at
16 weeks post-transplantation (p = 0.0001). Mice with CD45.1+ chimerism
<0.3% were considered as non-responders.
(F) For serial transplantation, 2 3 106 sorted CD45.1+ bone marrow cells from
either control or leukemic mice and appropriately adjusted per HSC numbers
of CD45.1+ cells from leukemic mice were transplanted into lethally irradiated
CD45.2 hosts. Rounds of transplantations with performed at 16-week in-
tervals. The proportion of PB generated from the CD45.1+ cells in recipient
mice was determined for each round of transplantation. Bar graphs indicate
chimerism after each round of transplantation; n = 4. Error bars represent
mean ± SD.
(G) PB samples from either 10 weeks post-transplant for CD45.1+ KSLs or
16 weeks post-transplant for CD45.1+ HSCs transplants, respectively, were
stained with CD45.1, CD45.2, and DAPI for viability. The bars show percent-
ages of the donor-type cells (CD45.1) that expressed myeloid (Gr-1 and
CD11b, filled), B-lineage (B220, striped), or T-lineage (CD4/8, open) markers in
the blood of individual recipients.
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Figure 4. Microarray Data Points to Cytokine Changes in the Pro-
genitor Cells from the Leukemic Exposure
(A) Hierarchical clustering with average linkage was used to generate the
heatmap of lineage-specific transcription factors from the control and
leukemic-exposed (Leuk Exp) progenitors.
(B) Enrichment plots of GSEA using control, leukemic-exposed, and leukemic
HSC and KSL expression data against a list of BCR-ABL-related gene
changes.
(C) We used an antibody-based protein array to measure cytokine changes in
the sera from our chimera mice, both control and transgenic. Results are
shown based on the normalization of the control sera. Error bars represent
mean ± SD.
676 Cancer Cell 27, 671–681, May 11, 2015 ª2015 Elsevier Inc.together, the leukemic bystander effects are dependent on tyro-
sine kinase activity, can drive IL-6 production, and are likely
reversible.
The Leukemic Environment Changes Normal
Progenitors through IL-6
The aforementioned findings raised questions related to revers-
ibility or prevention of disease through protection of normal
hematopoiesis by manipulation of the CML inflammatory envi-
ronment. We designed experiments to determine whether the
observed IL-6 dysregulation contributed to the changes
described earlier in the leukemic-exposed stem and progenitor
cells. Therefore, we analyzed chimeric mice lacking essential
components of the IL-6 signaling pathway, specifically IL-6Ra.
Consequently, MxCre IL-6Raflox/flox and MxCre+ IL-6Raflox/flox
mice were treated with polyI:C every other day for three total in-
jections to excise IL-6Ra. At this point, the mice had no obvious
abnormalities in hematopoiesis. Since these mice were on a
CD45.2+ background similar to our BCR-ABL leukemic model,
we used lineage-depleted marrow cells from the MxCre IL-
6Raflox/flox and MxCre+ IL-6RaD/D mice and labeled these two
groups of cells with a lentiviral GFP. GFP+ cells were sorted
and co-transplanted with control or transgenic (BCR-ABL)
bone marrow into lethally irradiated congenic recipients and
kept on Tet treatment to prevent disease (Figure 5A). At 16weeks
post-transplantation, we induced the expression of BCR-ABL
(Tet removal), and the GFP+ cells were then analyzed for their
ability to make either lymphoid- or myeloid-lineage cells (Fig-
ure 5B). MxCre+ GFP+ cells maintained their B lymphopoiesis,
even though they were in a leukemic environment, implicating
IL-6 signaling in lymphoid-lineage suppression and myeloid
expansion. Furthermore, GFP+ MxCre+ IL-6RaD/D KSLs from
the leukemic mice had no intrinsic changes as assayed by our
B-lineage differentiation in vitro assay (Figure 5C). Even though
normal differentiation from the leukemic-exposed cells was
restored in the IL-6RaD/D-transplanted cells, this did not hinder
the progression of CML disease in the CD45.2+ cells.
For therapeutic applications where targeting the inflammatory
environment might rescue normal differentiation as well as per-
turb the leukemic cells, we attempted to block IL-6 using an anti-
body against the cytokine. Therefore, chimeras were prepared,
and 16 weeks later, leukemia was induced by withdrawal of
Tet. After 2 weeks off Tet when increased CD45.2+ cells are
observed in the PB, groups of mice received either immunoglob-
ulin G (IgG) control antibody or an anti-IL-6 every other day
(0.2 mg/kg) for 6 weeks. Remarkably, the anti-IL-6-treated
mice showed no signs of disease such as splenomegaly or
myeloid expansion in hematopoietic tissues (Figures 5D and
5E). Only residual disease could be detected in the bone marrow
of these mice (Figure S4A). It should be noted that this treatment
did not eliminate the leukemic-initiating cells, as mice taken off
anti-IL-6 therapy eventually developed CML-like disease (Fig-
ure S4B). These treatments were unique to IM and anti-IL-6,
as treatment with anti-GM-CSF or anti-IL-1a did not lead to
significant cell death of leukemic bone marrow cells in culture(D) Enrichment plots of GSEA using control, leukemic-exposed, and leukemic
HSC and KSL expression data against a list of IL-6-related gene changes.
See also Figure S3.
Figure 5. Inhibition of IL-6 Signaling Protects Normal Progenitor
Cells
(A) Cartoon of themethod used to determine leukemic-exposed KSLs skewing
to the myeloid lineage was dependent on IL-6Ra signaling. CD45.2+ BCR-ABL
leukemic cells were transplanted with CD45.2+ GFP+ MxCre+ IL-6RaD/D cells
or CD45.2+ GFP+ MxCre IL-6Raflox/flox cells and kept on Tet for 16 weeks
before the removal of Tet. Pepcb/BoyJ is themouse name for CD45.1 B6mice.
lenti, lentivirus.
(B) Contour plots from staining of PB gating on GFP+ and GFP cells for B220/
CD3 and B220/Mac1-Gr1. Top panels show the control chimera, while
the bottom panels show the leukemic. GFP+ MxCre cells (center panels)
contain IL-6Raflox/flox cells. GFP+ MxCre+ cells are excised for IL-6Ra (right
panels); n = 4.
(C) GFP+ KSL cells from control or leukemic mice were sorted and co-cultured
on OP9 stromal cells for B-lineage differentiation. Flow cytometry plots show
CD19 versus Mac1 staining from control and leukemic mice containing either
IL-6Raflox/flox or MxCre+ IL-6RaD/D cells. Quantification of the percentages of
B-lineage cells andmyeloid cells derived from these cultures are plotted; n = 4.
Error bars represent mean ± SD.
(D) Splenic numbers andmorphology from IgG- and anti-IL-6-treated leukemic
mice are shown. Mice were injected intravenously with anti-IL-6 diluted in PBS
(0.2mg/kg). Antibody-injected controls were similarly injected with IgG in PBS.
Two weeks after removal from Tet, mice were injected ever other day for
6 weeks. Mice were then euthanized, and total cell numbers from the spleens
of control, leukemic IgG-, and anti-IL-6-leukemic-treated mice were obtained;
n = 5. Error bars represent mean ± SD.
(E) Flow cytometry plots of CD45.1+ myeloid cells (Mac1+ Gr-1+) from the
spleens of control or leukemic IgG- and anti-IL-6-treated mice. Spleens were
stained for viable CD45.1, CD45.2, Mac1, and Gr1; n = 4.
(F) Sorted control, leukemic-exposed, and leukemic KSLs were cultured in
colony assays in the presence or absence of anti-IL-6 at two doses. Colonies
were counted, and relative colony numbers were determined compared to
untreated cells for each population; n = 3. Error bars represent mean ± SD.
See also Figure S4.(Figure S4C).Moreover, treatment with anti-IL-6 in colony assays
with control, leukemic-exposed, or leukemic KSL showed that
the leukemic cells were specifically sensitive to this treatment
with respect to colony formation (Figure 5F). These data suggest
that the BCR-ABL leukemic environment promotes the disease
and impacts the neighboring non-transformed cells through IL-
6. Furthermore, this environment can be altered through block-
ing the inflammatory signature.
IL-6 Disrupts Normal Stem and Progenitor Cell Function
in Human CML
These experimental animal findings may lead one to question
their relevance to human disease, but chronic-phase CML has
not been satisfactorily reproduced by transplantation into immu-
nodeficient mice (Dazzi et al., 1998) (as well as the observations
of R.S.W. and G.A.). Therefore, we exploited culture approaches
similar to those described to evaluate bystander changes in our
mouse model. We cultured lentiviral GFP-labeled, sorted CD34+
adult bone marrow cells that were mixed with bone marrow cells
from either control (healthy) or chronic-phase CML patients.
As seen with our mouse model of CML, human cultures had
increase IL-6 as assessed by real-time PCR (Figure 6A). Further-
more, CML bonemarrow exposure causedGFP+CD34+ progen-
itors to expand more than twice that observed from co-culture
with normal patient bone marrow (Figure 6B). This increase in
GFP+ cells was inhibited by addition of an anti-IL-6 antibody.
Additionally, CD34+ progenitors co-cultured with CML bone
marrow had reduced B-lineage potential as assayed duringCancer Cell 27, 671–681, May 11, 2015 ª2015 Elsevier Inc. 677
Figure 6. Increased Proliferation and Skewed Differentiation of
Normal Human CD34+ Progenitors when Mixed with Human CML
Cells
(A) Cytokine IL-6 mRNA levels from cultured patient bone marrow (healthy,
chronic-phase CML, or mixed) were measured against GADPH and normal-
ized to healthy controls; n = 5. Error bars represent mean ± SD.
(B) Bar graph showing the yield per input of GFP+ cells when cultured with
control or CML bone marrow with or without anti-IL-6. Bead-enriched CD34+
cells from human adult bone marrow were labeled with a lentiviral GFP re-
porter. These cells were then cultured with whole adult bone marrow from
healthy patients (control) or thosewith chronic-phaseCML (leukemic exposed)
on stromal cells (MS5). Additionally, wells contained either IgG or anti-IL-6 as
indicated (5 mg/ml). These cells were cultured for 96 hr with Flt3 ligand (Flt3L),
thrombopoietin (TPO), and IL-3 and then counted and analyzed by flow cy-
tometry for total GFP+ cells; n = 3. Error bars represent mean ± SD.
(C) CD34+ GFP-marked cells were co-cultured with healthy bone marrow
(Control) or chronic-phase CML (leukemic exposed; Leuk Exp) on stromal
cells. These cultures were maintained with IL-7, stem cell factor (SCF), and
Flt3L for 1 week and then an additional 3 weeks with only SCF and Flt3L. As
indicated, some wells contained anti-IL-6. After the 4-week culture, GFP+
human cells were analyzed by flow cytometry for expression of CD19 and
Mac1; n = 3.
(D) GFP+ CD34+ cells from either control or leukemic-exposed cultures were
stained for annexin V to determine the relative apoptosis in these conditions,
and lines indicate the mean; n = 3. Error bars represent mean ± SEM.
(E) Sorted GFP+ CD34+ cells were analyzed from control and CML cultures
(with or without anti-IL-6) after staining with Pyronin Y and Hoescht to deter-
mine cell cycle status; n = 3.
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with anti-IL-6 was able to restore B-lineage potential (Figure 6C).
From these culture conditions, we were able to determine that
CML cells did not significantly increase apoptosis of the GFP-
marked cells (Figure 6D). Moreover, CML cells caused not only
the expansion of the GFP+ CD34+ progenitors but also their divi-
sion, a phenomenon that was also IL-6 dependent (Figure 6E). As
seen with our murine studies, anti-IL-6 was able to inhibit colony
formation of both chronic-phase and IM-resistant CML bone
marrow patient samples (Figure 6F). We conclude that changes
in cytokine levels, specifically those of IL-6, in the CML environ-
ment are responsible for altered differentiation and function of
normal stem and progenitor cells. Our models underscore the
significant effect of the leukemic cells and environment on con-
ditioning both leukemic and normal stem and progenitor cells.
We conclude that changes in cytokine levels, specifically those
of IL-6, in the CML are mostly responsible for the altered differ-
entiation and function of normal stem and progenitor cells while
promoting the disease.
DISCUSSION
Our models underscore the significance of the leukemic cells on
conditioning both leukemic and normal stem and progenitor cells.
First, and confirming the recent work of others (Begley and Ellis,
2012; Krause et al., 2013; Reynaud et al., 2011; Schepers et al.,
2013), leukemic cells alter neighboring non-transformed hemato-
poietic cells; however, the direct impact on stem and progenitor
cell function was not previously addressed. Second, these
leukemic-exposed normal cell counterparts acquire characteris-
tics of the transformed cells, with changes dependent on their
stage of differentiation. That is, HSCs are altered differently from
the changes observed in KSLs/progenitors. Characteristics im-
printed on leukemic-exposed HSCs included reconstitution de-
fects but not homing or differentiation potential. Alterations in
KSLs were much more striking. Exposure of these progenitors
to leukemic cells induced loss of lymphopoietic potential and
enhanced myeloid potency. In addition, the normal progenitors
entered cell cycle and mimicked leukemic cells with respect to
gene expression. Third, an IL-6 signature was prominent in the
transcriptome profile, leading us to functional studies involving
this cytokine. Furthermore, IL-6 signaling was necessary for
acquisition of the characterized bystander properties by normal
progenitors. Finally, human leukemic cells perturbed neighboring
progenitors through the production of IL-6 similar to that demon-
strated by our mouse model. We believe that these observations
will focus attention on how changes in normal hematopoietic cells
that reside near transformed ones in bone marrow can lead to
therapeutics targeting the leukemic cells by altering the inflamma-
tory profile from the disease.
Our model was previously shown to closely resemble the
chronic phase of human CML (Koschmieder et al., 2005). More-
over, we are encouraged that two recent reports are closely rele-
vant to our study and show the reproducibility of the science(F) Bone marrow from healthy, chronic-phase CML, or IM-resistant CML
was cultured in Methocult4435 for colony formation with or without human
anti-IL-6. Colony numbers are presented as relative to the healthy untreated
control; n = 2. Error bars represent mean ± SD.
(Begley and Ellis, 2012; Schepers et al., 2013; Zhang et al., 2012).
In these studies, they lethally irradiated our inducible BCR-ABL
transgenic or wild-type controls. The animals were then used
as recipients of HSPCs from leukemic or normal marrow from
non-irradiated mice. The leukemic host, mainly the stromal
niche, was a poor host for normal hematopoiesis. It is important
to note, however, that one group did not record IL-6 overexpres-
sion from the environment but rather the changes in the cellular
environment (Zhang et al., 2012).
In our work, we closely monitored the normal hematopoietic
cells over time following BCR-ABL activation and observed rapid
changes in progenitors. After 1 month of leukemic exposure,
KSL numbers were greatly expanded, and they had almost
completely lost their ability to generate lymphocytes. This might
be explained in terms of selective growth of myeloid precursors
and/or re-direction away from lymphopoiesis. HSC changes
were more subtle and obvious only in transplantation assays, a
phenotype that remained even after treating the mice with anti-
IL-6. Although we saw little changes in proliferation and differen-
tiation of HCS, these changes may occur at earlier stages of the
disease, particularly at onset from perturbation of leukemic stem
cells within a similar niche (Zhang et al., 2012). Our data and
others suggest that HSC express little to no IL-6Ra and may,
therefore, be less responsive to this specific inflammatory cyto-
kine (Maeda et al., 2005). We are interested to determine other
cytokines or environmental changes specifically mediating
changes in HSCs. However, we can conclude that residence
near leukemic cells provides several disadvantages to cells lack-
ing the BCR-ABL fusion protein. Their inability to self-renew and
sustain balanced hematopoiesis would allow them to be out-
competed by transformed cells over time.
It has previously been suggested that cytokines create a pro-
inflammatory environment during CML development and that
this provides a proliferative advantage to leukemic cells (Holy-
oake et al., 1999; Zhang et al., 2012; Zhang and Ren, 1998).
We observed a conspicuous IL-6 signature in leukemic-exposed
progenitors, and there are precedents for the importance of this
factor in CML. Two groups observed that serum IL-6 was
elevated in sera of leukemic animals (Reynaud et al., 2011;
Zhang et al., 2012). Additionally, IL-6 secretion increases with
CML development in patients (Anand et al., 1998; Reynaud
et al., 2011; Schmidt et al., 2011; Zhang et al., 2012). Further-
more, Reynaud et al. (2011) found that disease progression
was inhibited when BCR-ABL was induced in hematopoietic
cells of IL-6-deficient mice. IL-6 is also capable of blocking a
discrete early stage of lymphopoiesis (Maeda et al., 2005). We
are not the first to find this inflammatory signature in CML; how-
ever, we were able to use antibody therapy to target the inflam-
matory environment in this model of leukemia.
We found that IL-6 drives normal progenitor changes in our
chimeric animal model of CML. Indeed, treatment of the mice
with neutralizinganti-IL-6 allowedprogenitor compositionanddif-
ferentiation to proceed normally for at least 6 weeks after BCR-
ABL activation. Tumor-initiating cells must have been spared
because the disease developed when antibody therapy was dis-
continued. HSC can propagate CML disease but are unlikely to
be direct targets of IL-6 because they lack critical receptor com-
ponents (Raaijmakers et al., 2010; Reynaudet al., 2011;Schemio-
nek et al., 2010). Thus, factors other than IL-6 might account forour finding that untransformed HSCs had reduced self-renewal
ability after residence in leukemic marrow and during therapy.
Moreover, Schepers et al., (2013) provide evidence that this loss
of HSC function could be accomplished by reprogramming stro-
mal cells as a result of the leukemic cells or environment. In that
context, it is interesting that, in human CML, chemokines can
inhibit theproliferationof normal hematopoietic cellswhile sparing
transformed ones, and similar interactions may be occurring
within the niche (Cashman et al., 1998; Eaves et al., 1993a,
1993b). The source of IL-6 produced in CML is still in question
and might involve multiple types of BCR-ABL-transformed cells.
The study by Zhang et al. (2012), noted earlier, suggested that ra-
dio-resistant stromal cellswerenot an important sourceof IL-6 ina
transplantation model similar to ours. On the other hand, inflam-
mation driven by TLR ligands and T-cell-produced interferons
can elicit IL-6 production in stromal elements (Zhao et al., 2014).
In addition to the results we observed in mice, neutralization of
IL-6 protected human CD34+ cells when exposed to CML cells.
Given the contribution of IL-6 to a wide range of human inflam-
matory diseases, clinically effective strategies have already
been developed for its neutralization (Tanaka et al., 2011). Our
results suggest that this approach might be an effective therapy
in drug-resistant CML or other leukemias with pro-inflammatory
signatures, specifically, those in which the leukemic cells are
also found to have an adverse impact on untransformed
bystander hematopoietic cells. From studying the non-trans-
formed cells in other models of leukemia, we hope to find and
target additional cell-autonomous environmental changes that
are necessary for propagation of the leukemic clones.
EXPERIMENTAL PROCEDURES
Mice/Human Samples
Inducible, transgenic SCL-tTa/BCR-ABLmice (Koschmieder et al., 2005) were
backcrossed into the B6 background and were maintained with administration
of Tet in the drinking water (0.5 g/l). BCR-ABL expression was induced by Tet
withdrawal for a minimum of 3 weeks. Mice were housed in a sterile barrier fa-
cility approved by the Institutional Animal Care and Use Committee (IACUC) at
the Beth Israel Deaconess Medical Center. Human samples were collected
with informed consent and approved by the institutional review board at the
Beth Israel Deaconess Medical Center.
Flow Cytometry
Single-cell suspensions from various organs were analyzed by flow cytometry
using the following monoclonal antibodies conjugated with phycoerythrin
(PE), PE-CY7, fluorescein isothiocyanate, allophycocyanin (APC), APC-Cy7,
or eFluor 450 obtained from BD PharMingen (BD), BioLegend, or eBioscience:
Mac-1/CD11b (M1/70), Gr-1 (8C5), CD3 (KT31.1), CD4 (GK1.5), CD8 (53-6.7),
B220 (RA3-6B2), CD19 (1D3), TER119 (TER-119), Sca1 (E13-161-7), c-Kit
(2B8), CD16/32 (2.4G3), Thy-1.2 (53-2.1), CD135 (AF2 10.1), CD48 (HM48-1),
CD45.1 (A20), CD45.2 (104), and CD150 (TC15-12F12.2). Stained cells were
analyzed with an LSRII flow cytometer and sorted using a FACSAria II (BD Bio-
sciences). Viable cells were identified by DAPI exclusion. Human stem cells/
primitive progenitors were isolated by sorting CD34+CD38 cells. Diva soft-
ware (BD) and FlowJo (Tree Star) were used for data acquisition and analysis,
respectively.
Proliferation and Cell Cycle Analysis
For proliferation analysis, BrdU was administered intraperitoneally (1 mg per
mouse), bone marrow cells were obtained 16 hr post-injection, and BrdU
incorporation into stem and progenitor populations was analyzed (Cappella
et al., 2008). Cell cycle was also analyzed using Pyronin Y andHoescht labeling
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Limiting Dilution Assay
HSCs or total bone marrow cells were collected as CD45.1+ from leukemic or
control mice 4 weeks following removal of Tet water; then, the number of cells
indicated to be injected per mouse was sorted into individual wells of a 96-well
plate containing 104wild-typeCD45.2+ bonemarrow (rescue cells) in PBS. The
contents of individual wells were injected into the retro-orbital venous sinus of
lethally irradiated CD45.2+ recipients (600 rads twice with a 3-hr interval). PB
was obtained from each mouse each month after transplantation for at least
4 months and analyzed by fluorescence-activated cell sorting (FACS). Cells
were stained with anti-CD45.1 and CD45.2 antibodies to distinguish donor-
derived cells from the host cells, as well as lineage-specific antibodies
Mac1, Gr1, B220, and CD3, to identify myeloid, B, and T lineages. A recipient
mouse was considered positive if CD45.1+CD45.2 cells were present in
myeloid and B and/or T cells and also constituted more than 0.3% of the cells
in the PB.
Bone Marrow Transplantation
For the initial experimental setup, 23 106 CD45.1+ bone marrow cells and 23
106 CD45.2 bonemarrow cells fromSCLtTa/BCR-ABLmicewere transplanted
through retro-orbital injection into lethally irradiated CD45.1 mice. Mice were
maintained on Tet before (2 weeks) and after transplantation for 16 weeks to
establish chimerism before induction of the transgenes.
Microarray Analysis
Robust multichip average (RMA) was run for all CEL files generated in this
study to obtain the probe-set expression data. The probe-set expression
data were then normalized using the cross-correlationmethod. GSEAwas car-
ried out with the normalized data by comparing the leukemic-exposed HSCs
or KSLs to their corresponding controls, respectively. The gene set database
used inGSEAwas themsigdb v3. For heatmap presentation of the significantly
changed transcription factors in the leukemic-exposed versus the control
setting, the normalized data were further log2 transformed, and the subtraction
of the mean of the means was carried out for each gene. Also, hierarchical
clustering with average linkage was used to generate the heatmap.
Statistical Analysis
The statistical significances were assessed by Student’s unpaired t test using
the GraphPad software.
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